ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,191.90
-1.23%
S&P ASX All Technology
3,746.90
-2.57%
Brent Oil
80.51
-0.13%
US Dollar vs AUD
1.62653
0.10%
Bitcoin
92,843.01
-1.74%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Poxel (POXEL) Share Price

Poxel

Poxel (POXEL)

EU
0.165
-0.0096
( -5.50% )
Updated: 19:57:06
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.165
Bid
0.166
Offer
0.1742
Volume
159,714
0.165 Day's Range 0.1812
0.115 52 Week Range 0.898
Market Cap
7.687M
Previous Close
0.1746
Open
0.1812
Last Trade
1460
@
0.165
Last Trade Time
19:50:32
Financial Volume
-
VWAP
-
Average Volume (3m)
427,373
Shares Outstanding
46,586,753
Dividend Yield
-
PE Ratio
-0.24
Earnings Per Share (EPS)
-0.75
Revenue
1.98M
Net Profit
-35.09M

About Poxel

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.poxelpharma.com
Headquarters
Lyon, Rhone, Fra
Founded
-
Poxel is listed in the Pharmaceutical Preparations sector of the Euronext with ticker POXEL. The last closing price for Poxel was 0.17 €. Over the last year, Poxel shares have traded in a share price range of 0.115 € to 0.898 €.

Poxel currently has 46,586,753 shares in issue. The market capitalisation of Poxel is 8.13 € million. Poxel has a price to earnings ratio (PE ratio) of -0.24.

Ask ADVFN Intelligence (AI)

POXEL Latest News

More News

Poxel : nombre d’actions et de droits de vote composant le capital social

Regulatory News: Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers...

10 January 2025
Business Wire

Availability of Poxel’s 2024 Half-Year Financial Report

Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic...

23 December 2024
Business Wire

Poxel publie ses résultats financiers pour le premier semestre 2024 et fait le point sur sa situation et ses perspectives financières

A la suite de la non-adoption de certaines délégations financières lors de l’Assemblée Générale du 28 novembre 2024 : Horizon de trésorerie significativement réduit Exigibilité du remboursement...

09 December 2024
Business Wire

Poxel : nombre d’actions et de droits de vote composant le capital social

Regulatory News: Poxel (Paris:POXEL) : Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers...

07 December 2024
Business Wire

Poxel Announces Results from November 28, 2024 Annual General Meeting

Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic...

29 November 2024
Business Wire

Poxel annonce la tenue de son Assemblée Générale le 28 novembre 2024 à 9h00 et la mise à disposition des documents préparatoires

Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies chroniques graves à...

07 November 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.023-12.23404255320.1880.2760.16314974590.20494898DE
40.041433.49514563110.12360.2940.12328120230.1904688DE
12-0.137-45.36423841060.3020.34450.1154273730.20230728DE
26-0.325-66.32653061220.490.7470.1153634380.36845064DE
52-0.303-64.74358974360.4680.8980.1153149420.46252054DE
156-4.521-96.47887323944.6864.8080.1151699270.73343185DE
260-12.515-98.698738170312.6813.220.1151530742.77325718DE

POXEL - Frequently Asked Questions (FAQ)

What is the current Poxel share price?
The current share price of Poxel is 0.165 €
How many Poxel shares are in issue?
Poxel has 46,586,753 shares in issue
What is the market cap of Poxel?
The market capitalisation of Poxel is EUR 8.13M
What is the 1 year trading range for Poxel share price?
Poxel has traded in the range of 0.115 € to 0.898 € during the past year
What is the PE ratio of Poxel?
The price to earnings ratio of Poxel is -0.24
What is the cash to sales ratio of Poxel?
The cash to sales ratio of Poxel is 4.24
What is the reporting currency for Poxel?
Poxel reports financial results in EUR
What is the latest annual turnover for Poxel?
The latest annual turnover of Poxel is EUR 1.98M
What is the latest annual profit for Poxel?
The latest annual profit of Poxel is EUR -35.09M
What is the registered address of Poxel?
The registered address for Poxel is 259/261 AVENUE JEAN JAURES - IMMEUBLE LE SUNWAY, LYON, RHONE, 69007
What is the Poxel website address?
The website address for Poxel is www.poxelpharma.com
Which industry sector does Poxel operate in?
Poxel operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALTHOMetavisio (Thomson Computing)
0.257 €
(26.60%)
1.95M
ALVGVEOM Group
0.1655 €
(26.34%)
23.01k
HYPDSHipay Group DS
0.001 €
(25.00%)
1.45k
ALCABCabasse SA
0.858 €
(19.17%)
6.64k
PROACProactis SA
0.066 €
(16.81%)
1,000
GNROGeNeuro SA
0.116 €
(-14.71%)
148.6k
ALTHETheraclion
0.24 €
(-14.29%)
8.78k
ALSGDSpineguard
0.2155 €
(-12.22%)
435.67k
ALVERVergnet
0.0016 €
(-11.11%)
2.48M
TDBSTonner Drones
0.0008 €
(-11.11%)
6.16M
ATOAtos SE
0.002 €
(0.00%)
422.31M
BCPBanco Comercial Portugues SA
0.478 €
(-0.46%)
8.28M
TDBSTonner Drones
0.0008 €
(-11.11%)
6.16M
ALCYBCybergun
0.0001 €
(0.00%)
5.55M
ALEUPEuroplasma
0.0339 €
(11.51%)
3.77M

Discussion

View Full Feed
tw0122 tw0122 12 minutes ago
$4.24 target one reached 
UVIX
FranCoRazon FranCoRazon 12 minutes ago
If it was correct yes. But there are a lot of assumptions and even more details not mentioned. People get more and more fooled by AI just like google.
LWLG
Wayne R Wayne R 26 minutes ago
It's a fashion statement and ecologically friendly
Investor2014 Investor2014 30 minutes ago
Whether you like it or not, it is a fact that in May 120 days will have passed since the CHMP accepted the Anavex MAA. That will be clock stop one in the EMA process, where it is highly unlikely there will no questions raised for Anavex to reply to and for which 90 days are available.

AVXL
ducci1 ducci1 33 minutes ago
Pivot Calcs: SPX Pivot--5841----R1--5875----R2--5924-----S1--5792----S2--5758----SPY Pivot--581----R1--584----S1--576-----Vix Pivot--19.30----R1--2055----R2--21.56----R3--23.82----S1--18.29 !!LOL!!
SPY
meshcan meshcan 33 minutes ago
Nobody forcing you to stay here unless you want and you most likely are benefiting from bashing Elite or shorting or day trading...otherwise what you are saying doesn't make sense.

I know many longs here are already millionaire with current price, ~0.5 pps, but I'm sure they are waiti
ELTP
along4zride along4zride 34 minutes ago
Get ready to be thrown under (FNMA) bus .
No way no how slick suit and haircut Wall Street huckster gives one cent care about hopeful investor. More than likely common share holder has been ginned up . Sheep ready for slaughter or should I say vultures .

FNMA
jxyzobrien jxyzobrien 41 minutes ago
tangerine Mussolini
Killing the market
layoffs all over
tariff news has not yet brought in long term sellers
market should be up sunday nite NOPE
Hi_Lo Hi_Lo 50 minutes ago
Lol!! I want profits!! What you want helps me in no way!!
Exactly. Because the truth with documentation that BCAP is a scam and Jake P. Noch is a serial scammer prevents scamming pumpers and liars like you from making profits by creating bagholders here. And that's part of my goal - and to h
BCAP
DiamondHealer95 DiamondHealer95 54 minutes ago
What do you expect and how can you back your thoughts? Thanks
KBLB
DiamondHealer95 DiamondHealer95 1 hour ago
I mean Kim said once they hit 1.5 metric tons they're open for business and they're about halfway there so..... You're a genius! Congrats on the business. I also run one with 100% positive feedback over 22 years so I get the perspective🤪

Also, in my Arby's voice "I have the
KBLB
DiamondHealer95 DiamondHealer95 1 hour ago
We've invested similarly
KBLB
sunspotter sunspotter 1 hour ago
Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.
VPLM
Flobewan Flobewan 1 hour ago
Marc loved your ides
tinojax tinojax 1 hour ago
I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........
PLUG
mrfence mrfence 1 hour ago
Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
[yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]
FMCC FNMA
IVRT IVRT 2 hours ago
In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25
BMXI
DewDiligence DewDiligence 2 hours ago
GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

ENTA
DewDiligence DewDiligence 2 hours ago
GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

Your Recent History

EU
POXEL
Poxel
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads